On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug against SARS-Cov-2.

The companies previously identified multiple compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).